98591-61-8

Upstream product

• 1204-75-7 3-hydroxyquinoxaline-2-carboxylic acid 

Downstream Products

• 1374849-85-0 (R)-(2-(3-chlorobenzyl)piperidin-1-yl)(3-hydroxyquinoxalin-2-yl)methanone 
• 109179-56-8 1-phenyl-3-(1-pyrrolidyl)-1H-pyrazolo<3,4-b>quinoxaline 
• 109179-55-7 3-acetamido-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 109179-50-2 3-acetoxy-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 109179-52-4 3-chloro-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 109179-49-9 3-hydroxy-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 109179-54-6 3-amino-1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 
• 33920-28-4 1-phenyl-1H-pyrazolo<3,4-b>quinoxaline 

Relevant academic research and scientific papers

INHIBITORS OF FATTY ACID BINDING PROTEIN

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein (“FABP”) inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose.

Synthesis of 1-Phenyl-1H-pyrazolo-quinoxaline (1-Phenylflavazole) Derivatives Substituted at 3-Position

3-Amino-, 3-chloro- and 3-hydroxy-1-phenyl-1H-pyrazoloquinoxalines (6,9 and 12) have been prepared starting from ethyl 2-hydroxyquinoxaline-3-carboxylate (1).The 3-amino derivative (12) is also obtained from a Hofmann reaction of 1-phenyl-1H-pyrazo